Emyria has completed a strongly supported placement, to support the scale-up of its MDMA-assisted therapy programs. In this interview, Emyria Managing Director Dr Michael Winlo explains the potential for the company’s new therapy program to treat Post-Traumatic Stress Disorder.Elyria is advancing the MDMA molecule itself and refining its interaction with primary neurotransmitters like serotonin and dopamine.
https://grafa.com/news/asx-video--emyria--asx-emd--to-scale-up-mdma-assisted-therapy-218562
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.7¢ |
Change
-0.003(6.00%) |
Mkt cap ! $31.21M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.8¢ | 4.6¢ | $47.20K | 1.003M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 197302 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 100000 | 1 |
View Market Depth
| Last trade - 15.58pm 12/09/2025 (20 minute delay) ? |
| EMD (ASX) Chart |